Hershey posts Q1 FY24 earnings, surpassing estimates with a 8.9% sales surge to $3.252 billion. Notably, North America Confectionery segment sees a 10.4% boost to $2.707 billion. With a robust gross margin expansion of 520 basis points to 51.5%, Hershey reports a 21.3% rise in gross profit to $1.67 billion.
Stocks look set to carry forward the upward momentum on Friday amid some earnings cheer, although a tinge of nervousness is evident ahead of the all-important non-farm payrolls report.
MariTide, formerly AMG 133, is an injectable form of drug targeting two gut hormones — gastric inhibitory polypeptide receptor, or GIP, and glucagon-like peptide 1, or GLP-1.